Abatacept in individuals at high risk of rheumatoid arthritis (APIPPRA): a randomised, double-blind, multicentre, parallel, placebo-controlled, phase 2b clinical trial. (2024)
Attributed to:
Study into the potentially therapeutic immunomodulatory effects of gp120 in autoimmune rheumatic disease
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1016/s0140-6736(23)02649-1
PubMed Identifier: 38364839
Publication URI: http://europepmc.org/abstract/MED/38364839
Type: Journal Article/Review
Parent Publication: Lancet (London, England)
ISSN: 0140-6736